Expert Interview
Reviewing the potential of the CanGaroo RM Antibacterial Envelope from Aziyo Biologics in light of its 'Not Substantially Equivalent determination' from the FDA
Ticker(s): AZYO, MDTInstitution: University of California, San Diego
- Associate Professor Cardiac Electrophysiology, Division of Cardiology at University of California, San Diego (UCSD).
- Currently manages >500 patients with Atrial Fibrillation.
- Clinical research investigator with advanced training, and his interests include epidemiology and clinical outcomes in patients with all types of cardiac arrhythmias. Dr. Hsu's research has resulted in publications in medical journals such as The New England Journal of Medicine, as well as several top cardiology journals, including Journal of the American College of Cardiology and Circulation.
Please describe your background and practice setting.
Added By: ben_adminHow many cardiac implantable electronic devices do you implant on a monthly basis?
Added By: ben_adminHow many of the CanGaroo envelopes have you utilized in the past 12 months?
Added By: ben_adminWhat is your opinion on the next generation device, utilizing rifampin and minocycline for bacterial protection?
Added By: ben_adminWhat do you think of the 'Not Substantially Equivalent determination' from the FDA? How will it impact the future of this envelope?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
